Will accurate PET / CT bring vitality to patients in advanced stage?
You are here: Home » News » Industry News » Will accurate PET / CT bring vitality to patients in advanced stage?

Will accurate PET / CT bring vitality to patients in advanced stage?

Views:5     Author:Site Editor     Publish Time: 2020-07-27      Origin:Site

prostate cancer

    According to China news network, Shanghai, June 12 the reporter learned on the 12th that the latest multidisciplinary comprehensive diagnosis and treatment research results of Chinese medical experts confirmed that accurate PET / CT can effectively detect prostate cancer metastases that can not be found by traditional imaging examination, and break the conventional recognition of "no surgical treatment as long as the metastasis" in the medical community, and provide more accurate imaging basis for the development of treatment plans for these patients.

    This means that in the future, doctors can develop individualized treatment plans based on the metastatic lesions found by accurate examination, so as to provide more effective and accurate treatment plan for patients with advanced prostate cancer, so as to greatly improve the cure rate and survival period of prostate cancer.

clinical cancer research


    Professor Ye Dingwei, director of Shanghai Institute of Urology, and Professor Song Shaoli, director of the Shanghai Institute of Urology, and Professor Song Shaoli, director of the Department of Urology, Fudan University Cancer Hospital, published online in the official journal of the American Cancer Association, clinical cancer research.

    Professor Ye Dingwei, who has been committed to early screening of prostate cancer in the community for many years, told reporters on the 12th that the proportion of patients with early-stage prostate cancer in China is still quite low. "The biggest difference between Chinese prostate cancer patients and developed countries in Europe and the United States is that 30% of patients in China are in the middle and advanced stage at the time of initial diagnosis, while patients in developed countries in Europe and America are mostly in early stage," he said

professor YDW


    It is reported that once the disease has developed to the middle and late stage at the time of initial diagnosis, it means that many patients have lost the opportunity of radical surgery, and these patients can only control the progress of the disease through endocrine therapy. The expert told reporters, "the patients who can receive radical surgery only account for one-third of the newly diagnosed patients." Professor Ye Dingwei said that almost all patients who received traditional endocrine therapy became drug-resistant prostate cancer after 1 to 2 years, and their condition deteriorated rapidly.

    In the past, the staging of patients with advanced stage mainly depended on traditional imaging examination, but due to the lack of accuracy, small metastatic lesions were often missed, resulting in the false appearance of "non metastasis" and delaying the treatment. Professor Ye Dingwei and Professor Song Shaoli, director of the Department of nuclear medicine, jointly studied and found that 73% of the patients who were considered "not metastatic" in traditional imaging examination had actually had lymph node or distant metastasis.

    The team mapped the distribution of oligo metastasis in patients with castration resistance (failure of endocrine therapy) in the world, opening a window for exploring new treatment methods for such patients. It was revealed that among the 114 lesions detected, bone metastasis accounted for about 52%.

    The researchers also changed the conventional understanding that "no surgical treatment can be performed as long as the metastasis is needed". They found that in the early stage of castration resistance (failure of endocrine therapy), about 51% of patients can undergo relevant surgery or radiotherapy. New research has benefited patients. After accurate imaging examination, Wang Dabo was found with two early metastatic lesions. Professor Ye Dingwei, on the basis of systemic treatment, formulated a comprehensive treatment method for him: local robotic surgery plus precise radiotherapy for metastatic lesions, and finally the lesions achieved complete remission after treatment.

    At present, the 5-year survival rate of prostate cancer patients in Fudan University Cancer Hospital is 82.6%, which is better than the domestic average of 69.2%. Professor Ye Dingwei said that with the close promotion of scientific research and clinical practice of multidisciplinary team, in the future, domestic patients with advanced prostate cancer will usher in more vitality.


(Note: picture from China News Network)


Our Company

Arcmoon Brand Management co.,Ltd selects high-quality and cost-effective products that are superior to the quality standards of the same industry,covering categories such as food,health care,daily care,etc.Further more,provide one-stop and all-round customer service.

Get In Touch

E-mail : sivan@arc-moon.com 
Add: Block D Tuspark, Xi’an, China.
High-Quality and Cost-Effective products, including food, health care, daily care, etc.
 

E-mail: sivan@arc-moon.com 
Tel/whatsapp: +86 135 7216 5720
Address:Block D Tuspark, Xi’an, 

Shaanxi Province, China

Quick Nav

Subscribe

Get latest updates and offers.

Copyright  Arcmoon Co.,ltd. All rights reserved. 丨Sitemap